Please assess the completion status of the following clinical trial:

Trial Title: Decitabine in Patients With Chronic Myelomonocytic Leukemia (CMML)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or older~* CMML diagnosis according to WHO criteria~* Stable excess in blood monocytes,\>1x10G/l and \>10% of WBC~* Bone marrow blasts \<20%~* Dysplasia of at least one lineage or clonality marker or blood monocytosis during more than 3 months w/o other explanation~* With:~  * if WBC \< or= 12 000/mm3: IPSS high or intermediate 2~ * if WBC \> 12 000/mm3: at least two of the following criteria: blast cells \> 5% in the bone marrow, clonal cytogenetic abnormality other than t(5;12)(q33;p13), anemia (Hb \< 100 g/l), thrombocytopenia (platelet count \< 100G/l), splenomegaly \> 5 cm below costal margin, extramedullary localization~* Either untreated or previously treated with~* Hydrea or Etoposide given orally~* non intensive chemotherapy~* intensive chemotherapy given more than 3 months before inclusion~* With performance status 0-2 on the ECOG scale~* With estimated life expectancy of at least 12 weeks~* With adequate organ function including the following:~  * Hepatic: total bilirubin \< 1.5 times upper limit of normal (ULN), alanine transaminase (ALT) and aspartate transaminase (AST) \< 3 times ULN~ * Renal: serum creatinine \< 1.5 times ULN, creatinine clearance \> 30 ml/min~* With informed consent~* Negative pregnancy and adequate contraception if relevant~Exclusion Criteria:~* Myeloproliferative/myelodysplastic syndrome other than CMML~* Acute blastic transformation of CMML with bone marrow blasts\>20%~* Patients eligible for allogenic bone marrow transplantation with identified donor~* CMML with t(5;12) or PDGFbetaR rearrangement that could receive Imatinib~* Previous treatment with a hypomethylating agent~* Age \< 18 years old~* Pregnancy or breastfeeding~* Performance status\> 2 on the ECOG Scale~* Estimated life expectancy \< 12 weeks~* Serious concomitant systemic disorder, including active bacterial, fungal or viral infection, that in the opinion of the investigator would compromise the safety of the patient and/or his/her ability to complete the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Decitabine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).